

# ProPharma Partners, Inc.

Is pleased to announce our representation of

## **Replidyne, Inc.**

In facilitating the Collaboration with  
**Sequoia Sciences, Inc.**

**Richard Hammel, Ph.D., James Chubb, Ph.D.  
Leslie Molony, Ph.D.  
Hayward, California**

**Tetsuo Imura  
Tokyo, Japan**

**Peter Cozens, Ph.D., Geoff Kitson, M.D.,  
Simon Gunning, Ph.D., Donna Hackett, Esq.  
London, UK**

---

Louisville, CO (Sept. 18, 2003): Replidyne's agreement with Sequoia Sciences, Inc. complements the Company's current discovery efforts by providing access to Sequoia's unique libraries of compounds isolated from plants. Sequoia's proprietary libraries contain structurally-diverse compounds that possess a wide range of potential pharmacological activities. Replidyne will be responsible for high- throughput screening of the libraries, lead optimization, development and commercialization, and will work with Sequoia on compound identification. Specific financial terms were not disclosed.

### **About Replidyne**

Replidyne is a specialty pharmaceutical company focused on developing and commercializing innovative anti-infective products to address a major, and growing, public health issue: bacterial resistance to existing antibiotics. The Company is pursuing novel mechanism-of-action antibacterial compounds that inhibit bacterial DNA replication. Additionally, the Company has recently acquired a major anti-bacterial program from GlaxoSmithKline. Replidyne's investors include HealthCare Ventures, Sequel Partners, Morgenthaler Ventures, Johnson & Johnson Development Corporation and GlaxoSmithKline.

*For additional information please visit [www.replidyne.com](http://www.replidyne.com).*